Detalhe da pesquisa
1.
Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.
Antimicrob Agents Chemother
; 57(12): 6122-30, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24080655
2.
Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.
Antiviral Res
; 206: 105403, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36041646
3.
HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells.
J Virol
; 84(13): 6505-14, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20410277
4.
An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral.
Antiviral Res
; 195: 105180, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551346
5.
Activity of Galidesivir in a Hamster Model of SARS-CoV-2.
Viruses
; 14(1)2021 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35062212
6.
Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism.
Antimicrob Agents Chemother
; 53(3): 1116-23, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19075055
7.
Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope.
Antimicrob Agents Chemother
; 53(3): 1124-31, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19075068
8.
In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc.
J Clin Pharmacol
; 48(10): 1179-88, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18676693
9.
Reliable genotypic tropism tests for the major HIV-1 subtypes.
Sci Rep
; 5: 8543, 2015 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-25712827
10.
HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.
AIDS Res Hum Retroviruses
; 26(1): 13-24, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20055594
11.
Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
AIDS
; 22(12): 1425-31, 2008 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-18614865
12.
Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene.
J Virol
; 77(12): 6743-52, 2003 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12767994